&l;p&g;Facebook&a;nbsp;is up 30% in the last three months. Of the eight Marketocracy managers who own Facebook, only Wayne Himelsein was willing to buy Facebook at current prices. Since no one is selling the stock, the consensus seems to be that Facebook is moderately undervalued right now. John Archer explains.
&l;img class=&q;dam-image getty size-large wp-image-969193348&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/969193348/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Facebook&s;s strong performance is probably not over. (Photo by Jaap Arriens/NurPhoto via Getty Images)
John first bought Facebook for his TAB fund in November 2016 at $122. He increased his position by 50% in July 2017 at $163. Two months later he increased his position by 66% paying $170. At $196, Facebook is 6% of his&a;nbsp;TAB&a;nbsp;fund.
&l;strong&g;Ken Kam&l;/strong&g;: All of your Facebook purchases are now solidly profitable. You are not buying Facebook at $196, but you aren&s;t selling it either. What do you think is &q;fair value&q; for Facebook?
Hot Undervalued Stocks To Buy Right Now: Cidara Therapeutics, Inc.(CDTX)
- [By Joseph Griffin]
Cidara Therapeutics (NASDAQ:CDTX) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.10), Bloomberg Earnings reports.
- [By Chris Lange]
Cidara Therapeutics Inc. (NASDAQ: CDTX) shares took a big step back on Monday, despite the firm reporting positive midstage results. Specifically, Cidara reported positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate rezafungin acetate.
- [By Stephan Byrd]
These are some of the media headlines that may have impacted Accern Sentiment’s analysis:
Get Cidara Therapeutics alerts:
Cidara Therapeutics (CDTX) Upgraded to Buy at WBB Securities (americanbankingnews.com) Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidaras Rezafungin for the Treatment of Invasive Fungal Infections (finance.yahoo.com) Cidara Therapeutics and Rutgers University awarded $5.5M grant from NIH to develop immunotherapy agents targeting gram-negative bacterial infections (seekingalpha.com) Cidara Therapeutics Announces Offering of Common Stock and Warrants (finance.yahoo.com) Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections (finance.yahoo.com)
Shares of CDTX stock traded up $0.30 during trading on Wednesday, hitting $5.20. 311,700 shares of the company were exchanged, compared to its average volume of 203,168. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.99 and a current ratio of 5.99. The stock has a market cap of $97.33 million, a P/E ratio of -1.64 and a beta of 2.05. Cidara Therapeutics has a twelve month low of $3.70 and a twelve month high of $8.80.
Hot Undervalued Stocks To Buy Right Now: Datawatch Corporation(DWCH)
- [By Lisa Levin]
On Thursday, the information technology shares surged 0.29 percent. Meanwhile, top gainers in the sector included Keysight Technologies, Inc. (NYSE: KEYS), up 12 percent, and Datawatch Corporation (NASDAQ: DWCH) up 6 percent.
Hot Undervalued Stocks To Buy Right Now: Cambrex Corporation(CBM)
- [By Money Morning Staff Reports]
Cambrex Corp. (NYSE: CBM) was founded in 1981 and is a leading supplier of generic active pharmaceutical ingredients (APIs).
Cambrex has more than 100 generic APIs, and 90 of them are commercially sold.
Hot Undervalued Stocks To Buy Right Now: Gevo, Inc.(GEVO)
- [By Logan Wallace]
Gevo, Inc. (NASDAQ:GEVO) reached a new 52-week high and low on Friday . The company traded as low as $0.22 and last traded at $0.23, with a volume of 20863 shares changing hands. The stock had previously closed at $0.27.
- [By Max Byerly]
Amyris Biotechnologies (NASDAQ: AMRS) and Gevo (NASDAQ:GEVO) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
- [By Joseph Griffin]
Gevo (NASDAQ:GEVO) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
Hot Undervalued Stocks To Buy Right Now: AtriCure Inc.(ATRC)
- [By Shane Hupp]
ValuEngine upgraded shares of AtriCure (NASDAQ:ATRC) from a hold rating to a buy rating in a research report report published on Saturday.
A number of other research firms have also weighed in on ATRC. Zacks Investment Research lowered shares of AtriCure from a buy rating to a hold rating in a report on Wednesday, May 2nd. BidaskClub raised shares of AtriCure from a hold rating to a buy rating in a report on Saturday, March 17th. Stifel Nicolaus raised their target price on shares of AtriCure from $22.00 to $23.00 and gave the company a buy rating in a report on Friday, April 27th. Needham & Company LLC raised their target price on shares of AtriCure from $23.00 to $26.00 and gave the company a buy rating in a report on Friday, April 27th. Finally, TheStreet raised shares of AtriCure from a d+ rating to a c- rating in a report on Friday, March 16th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $25.00.
Hot Undervalued Stocks To Buy Right Now: JAKKS Pacific, Inc.(JAKK)
- [By Joseph Griffin]
ValuEngine upgraded shares of Jakks Pacific (NASDAQ:JAKK) from a sell rating to a hold rating in a research report released on Saturday.
Several other brokerages have also recently weighed in on JAKK. Stifel Nicolaus lowered their target price on Jakks Pacific from $2.70 to $2.50 and set a hold rating on the stock in a report on Friday, April 27th. Zacks Investment Research cut Jakks Pacific from a hold rating to a sell rating in a report on Monday, April 30th. Finally, BMO Capital Markets restated a market perform rating and set a $2.50 target price (down from $3.50) on shares of Jakks Pacific in a report on Friday, February 23rd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Jakks Pacific has a consensus rating of Hold and a consensus target price of $2.69.
- [By Joseph Griffin]
JAKKS Pacific, Inc. (NASDAQ:JAKK) – Equities research analysts at Jefferies Financial Group raised their Q2 2018 EPS estimates for JAKKS Pacific in a report issued on Monday, June 18th. Jefferies Financial Group analyst S. Wissink now expects that the company will earn ($0.50) per share for the quarter, up from their prior forecast of ($0.63). Jefferies Financial Group also issued estimates for JAKKS Pacific’s Q4 2018 earnings at ($0.31) EPS, FY2018 earnings at ($0.56) EPS, Q3 2019 earnings at $0.50 EPS and FY2019 earnings at $0.05 EPS.